Nachrichten zur Myriad Genetics Aktie

Myriad Genetics, Inc. (MYGN) Q3 2023 Earnings Call Transcript

…

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q3

Myriad Genetics (MYGN) third-quarter 2023 revenues increase year over year, driven by strong testing volume improvement across all its businesses.…

Global Hereditary Testing Market Size To Worth USD 13.14 Billion By 2032 | CAGR of 7.8%

The Global Hereditary Testing Market Size was valued at USD 6.20 Billion in 2022 and the Worldwide Hereditary Testing Market…

Myriad Genetics Appoints Sam Raha as Chief Operating Officer

SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…

QIAGEN N.V.: QIAGEN und Myriad Genetics schließen Partnerschaft und treiben Entwicklung von Begleitdiagnostika für Krebs voran

Partnerschaft umfasst die Entwicklung von im Labor entwickelten (LDT) und vertriebsfähigen diagnostischen Begleittests auf Kit-Basis // Vereinte Stärken in den…

GNW-Adhoc: QIAGEN und Myriad Genetics schließen Partnerschaft und treiben Entwicklung von Begleitdiagnostika für Krebs voran

^Partnerschaft umfasst die Entwicklung von im Labor entwickelten (LDT) und vertriebsfähigen diagnostischen…

GlobeNewswire: QIAGEN und Myriad Genetics schließen Partnerschaft und treiben Entwicklung von Begleitdiagnostika für Krebs voran

QIAGEN und Myriad Genetics schließen Partnerschaft und treiben Entwicklung von Begleitdiagnostika für Krebs voran Partnerschaft umfasst die Entwicklung von im…

Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only test Myriad can conduct prospective clinical…

Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

Research will use Myriad’s high-definition MRD testing platform based on whole-genome sequencing Research will use Myriad’s high-definition MRD testing platform…

Myriad Genetics (MYGN) Teams Up to Assess Breast Cancer Risk

Myriad Genetics (MYGN) announces collaboration with Onsite Womens Health to develop a breast cancer risk assessment program....…

Myriad Genetics to Host Investor Day on September 19, 2023

SALT LAKE CITY, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…

Myriad Genetics (MYGN) Adds ARR to Prolaris Biomarker Test

Myriad Genetics (MYGN) announces the integration of ARR into the Prolaris prostate cancer prognostic test....…

Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®

Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1...…

Myriad Genetics (MYGN) Unveils GeneSight Test Enhancement

Myriad Genetics (MYGN) GeneSight report will contain details on how a patients smoking history may affect their metabolism of certain…

Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

SALT LAKE CITY, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing…

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss

Strong testing volume improvement across all businesses drives Myriad Genetics (MYGN) Q2 performance....…

Myriad Genetics Inc. Q2 Earnings Summary

WASHINGTON (dpa-AFX) - Below are the earnings highlights for Myriad Genetics Inc. (MYGN):Earnings: -$116.1 million in Q2 vs. -$14.1 million…

Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023

SALT LAKE CITY, July 27, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…

Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment

RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers...…

Myriad Genetics announces $90M asset-based credit facility

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K MYRIAD GENETICS INC For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform

Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response Myriad to support MD Anderson…

Myriad Genetics to Participate in Goldman Sachs Healthcare Conference

SALT LAKE CITY, June 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…

Insiderhandel: Aufsichtsrat verkauft Aktien von Myriad Genetics im Wert von 198.760$

Spiegelman, Daniel K. - Aufsichtsrat - Tag der Transaktion: 2023-06-02...…

Form 8-K MYRIAD GENETICS INC For: Jun 01

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics

SALT LAKE CITY, May 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…

Myriad Genetics (MYGN) Adds New Test to Oncology Portfolio

Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test....…

Goldman Sachs Maintains Myriad Genetics Buy Recommendation

Goldman Sachs has maintained coverage of Myriad Genetics with a Buy recommendation....…

Goldman Sachs Upgrades Myriad Genetics

Goldman Sachs has upgraded its outlook for Myriad Genetics to Buy....…

Myriad Genetics rises as Goldman upgrades on growth potential

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Myriad Genetics Soars on Double Upgrade from Goldman

Analysts say they expect the company to be operating cash flow positive in 2023....…

Myriad Genetics Earns 2023 Great Place to Work Certification™

SALT LAKE CITY, May 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…

Myriad Genetics Inc. Q1 Loss Increases, misses estimates

WASHINGTON (dpa-AFX) - Myriad Genetics Inc. (MYGN) announced Loss for its first quarter that increased from the same period last…

Myriad Genetics reports Q1 results, narrows FY 2023 guidance

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Immunovia AB appoints new CEO

April 29, 2023, Lund, Sweden LUND, SWEDEN – As a next step in focusing on the US market The Board of Directors…

Myriad Genetics (MYGN) Gets Permit to Expand Tumor Testing

Myriad Genetics (MYGN) and Intermountain Precision Genomics receive the New York State Clinical Laboratory Permit to offer solid tumor testing…

77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey

Medication failure leads 45% of respondents with depression and/or anxiety to turn to unhealthy coping mechanisms Medication failure leads 45% of…

Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification

Intermountain Precision Genomics Laboratory receives certification from NYS Department of Health Clinical Laboratory Evaluation Program Intermountain Precision Genomics Laboratory receives…

dpa-AFX ProFeed